Investigating the role of serotonin receptors in Alzheimer's disease symptoms
5-HT 2C Receptor and Alzheimer's Disease
This study is looking at how a specific serotonin receptor might affect behaviors like aggression and social interactions in Alzheimer's disease, using a mouse model that reflects some genetic changes seen in people with the condition, to find new ways to help improve the lives of those living with Alzheimer's.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Baylor College of Medicine NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-10928224 on NIH RePORTER |
What this research studies
This research focuses on understanding how serotonin receptors, specifically the 5-HT 2C receptor, are involved in the neuropsychiatric symptoms of Alzheimer's disease (AD), such as aggression and impaired sociability. The study utilizes a mouse model that mimics genetic mutations found in humans with cognitive deficits to explore the effects of serotonin signaling on behavior and memory. By examining these mechanisms, the research aims to identify potential therapeutic targets for improving the quality of life for AD patients. The approach includes both genetic analysis and behavioral assessments in the mouse model.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's disease who exhibit neuropsychiatric symptoms such as aggression or social withdrawal.
Not a fit: Patients with Alzheimer's disease who do not exhibit neuropsychiatric symptoms may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that alleviate neuropsychiatric symptoms in Alzheimer's patients, improving their overall care and quality of life.
How similar studies have performed: Previous research has indicated that targeting serotonin signaling may improve symptoms in neuropsychiatric disorders, suggesting potential success for this novel approach in Alzheimer's disease.
Where this research is happening
Houston, United States
- Baylor College of Medicine — Houston, United States (Active)
Researchers
- Principal investigator: Xu, Yong — Baylor College of Medicine
- Study coordinator: Xu, Yong
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.